Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour
Launched by SAMUEL LUNENFELD RESEARCH INSTITUTE, MOUNT SINAI HOSPITAL · Mar 23, 2012
Trial Information
Current as of June 01, 2025
Terminated
Keywords
ClinConnect Summary
The study will be conducted as a randomized trial with two arms: Group I- continuous infusion of remifentanil with stepwise increase in infusion rates and Group II- demand bolus only with stepwise increase in bolus dose, as per the patient's analgesic requirement. Visual analog scores will be the primary outcome. Maternal and fetal side effects will be recorded. The results of this study will determine the regimen that suits the patients needs for painless labor with high efficacy, less adverse effects and a higher patient satisfaction.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent
- • Term pregnancy in labour with singleton fetus in cephalic presentation
- • Patients requesting systemic analgesia
- • Patients with contraindication for regional anesthesia without fetal compromise (coagulopathy, thrombocytopenia, refusal, etc.)
- Exclusion Criteria:
- • Refusal to sign written informed consent
- • Inability to communicate in English
- • Opioid dependence or addiction
- • Patients on Methadone
- • Allergy or hypersensitivity to remifentanil
- • Fetal heart rate abnormalities
- • Fetal congenital anomalies
About Samuel Lunenfeld Research Institute, Mount Sinai Hospital
The Samuel Lunenfeld Research Institute at Mount Sinai Hospital is a leading biomedical research facility dedicated to advancing our understanding of human health and disease. Renowned for its innovative research programs, the institute focuses on areas such as cancer, genetics, and reproductive health, fostering collaboration among top-tier scientists and clinicians. With a commitment to translating research findings into clinical applications, the Samuel Lunenfeld Research Institute plays a pivotal role in the development of novel therapies and interventions, thereby contributing to improved patient outcomes and the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Mrinalini Balki, MD
Principal Investigator
MOUNT SINAI HOSPITAL
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials